Restoring the tumour suppressive function of p53 as a parallel strategy in melanoma therapy

A Code for RanGDP Binding in Ankyrin Repeats Defines a Nuclear Import Pathway

(2014) Min Lu et al.   CELL

Drugging the p53 pathway: understanding the route to clinical efficacy

(2014) Kian Hoe Khoo et al.   NATURE REVIEWS DRUG DISCOVERY

MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program

(2013) Z. Y. Xu-Monette et al.   BLOOD

Directed Phenotype Switching as an Effective Antimelanoma Strategy

(2013) Magalí Sáez-Ayala et al.   CANCER CELL

Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP

(2013) Min Lu et al.   CANCER CELL

DNp73 Exerts Function in Metastasis Initiation by Disconnecting the Inhibitory Role of EPLIN on IGF1R-AKT/STAT3 Signaling

(2013) Marc Steder et al.   CANCER CELL

BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage

(2013) V. J. Mar et al.   CLINICAL CANCER RESEARCH

p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis

(2013) Rubeta N. Matin et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Impaired PIASy–Tip60 signaling weakens activation of p53 in melanoma

(2013) Alexander J. Lakhter et al.   MELANOMA RESEARCH

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

p53 Efficiently Suppresses Tumor Development in the Complete Absence of Its Cell-Cycle Inhibitory and Proapoptotic Effectors p21, Puma, and Noxa

(2013) Liz J. Valente et al.   Cell Reports

Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence

(2012) Tongyuan Li et al.   CELL

MAPK and PI3K/AKT mediated YB-1 activation promotes melanoma cell proliferation which is counteracted by an autoregulatory loop

(2012) Tobias Sinnberg et al.   EXPERIMENTAL DERMATOLOGY

MEK'ing the Most of p53 Reactivation Therapy in Melanoma

(2012) John T. Lee et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Role of Tip60 in Human Melanoma Cell Migration, Metastasis, and Patient Survival

(2012) Guangdi Chen et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Structural Basis for ASPP2 Recognition by the Tumor Suppressor p73

(2012) Peter Canning et al.   JOURNAL OF MOLECULAR BIOLOGY

MDM4 is a key therapeutic target in cutaneous melanoma

(2012) Agnieszka Gembarska et al.   NATURE MEDICINE

RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

(2012) Fei Su et al.   NEW ENGLAND JOURNAL OF MEDICINE

Camptothecin induces p53-dependent and -independent apoptogenic signaling in melanoma cells

(2011) E. Rudolf et al.   APOPTOSIS

P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation

(2011) Kelly A Avery-Kiejda et al.   BMC CANCER

Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression

(2011) Colleen A. Brady et al.   CELL

iASPP and Chemoresistance in Ovarian Cancers: Effects on Paclitaxel-Mediated Mitotic Catastrophe

(2011) L. Jiang et al.   CLINICAL CANCER RESEARCH

Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma

(2011) J de Lange et al.   ONCOGENE

Abnormal MDMX degradation in tumor cells due to ARF deficiency

(2011) X Li et al.   ONCOGENE

Inhibitor of apoptosis-stimulating protein of p53 (iASPP) prevents senescence and is required for epithelial stratification

(2011) M. Notari et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Resistance to MEK Inhibitors: Should We Co-Target Upstream?

(2011) P. I. Poulikakos et al.   Science Signaling

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation

(2010) Tamara Terzian et al.   Pigment Cell & Melanoma Research

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

(2010) E. W. Joseph et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Role of BRAF Mutation and p53 Inactivation during Transformation of a Subpopulation of Primary Human Melanocytes

(2009) Hong Yu et al.   AMERICAN JOURNAL OF PATHOLOGY

A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis

(2009) Maddalena Adorno et al.   CELL

TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use

(2009) M. Olivier et al.   Cold Spring Harbor Perspectives in Biology

iASPP Inhibition: Increased Options in Targeting the p53 Family for Cancer Therapy

(2008) H. S. Bell et al.   CANCER RESEARCH

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

A complex barcode underlies the heterogeneous response of p53 to stress

(2008) Fiona Murray-Zmijewski et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

The common mechanisms of transformation by the small DNA tumor viruses: The inactivation of tumor suppressor gene products: p53

(2008) Arnold J. Levine   VIROLOGY